Revvity, Inc. logo

Revvity, Inc.

TickerRVTYVenueUSSectorHealthcarePrimary listingBeta1.09
$152.9+0.18%
FinScore42

Revvity, Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $17.0B. Its FinScore is 42/100; its highest-scoring layer is Momentum (79) and its lowest is Growth (18). The shares trade at 71.7x trailing earnings and are up 56% year to date.

Market cap
$17.0B
P/E (TTM)
71.7x
Dividend yield (TTM)
0.18%
ROE
3.3%

Share price performance

Loading chart…

About Revvity, Inc.

www.revvity.com

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Profile
Sector
Healthcare
Industry
Medical - Diagnostics & Research
HQ
United States
Fiscal year-end
December
Trading currency
USD
Reporting currency
USD
Fundamentals updated
75 days ago
Market
Market cap
$17.0B
Shares outstanding
111.6M
P/E (TTM)
71.7x
Dividend yield (TTM)
0.18%
Beta (issuer)
1.06
Revenue (latest FY)
$2.9B

Revenue breakdown

FY 2025$2.9B
  • Life Sciences
    50.1%$1.4B
  • Diagnostics
    49.9%$1.4B

FinScore

As of 2026-10-19
Overall42
Quality62
Growth18
Value26
Momentum79
Relative Strength21

Snapshot

Ownership

As of 2026-06-30
Institutional
100.0%
Insider
0.2%
Free float
91.9%
Top-5 institutional holders
45.1%
Shares outstanding
111.6M
Sign up to see the top holders

Sign up or log in to see Analysis

Analysis for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Financials

Financials for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Estimates

Estimates for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Peers

Peers for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see Valuation

Valuation for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.

Sign up or log in to see News

News for Revvity, Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.